key: cord-0923517-s6zsr0eu
authors: Lo, Chris Wai Hang; Fei, Yue; Cheung, Bernard Man Yung
title: Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
date: 2021-03-05
journal: Card Fail Rev
DOI: 10.15420/cfr.2020.19
sha: 72b737800164737604893393c8d088a3b65bc8e0
doc_id: 923517
cord_uid: s6zsr0eu

Type 2 diabetes is among the most prevalent chronic diseases worldwide and the prevention of associated cardiovascular complications is an important treatment goal. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are second-line options after metformin, while cardiovascular outcome trials have been conducted to establish the cardiovascular safety of these antidiabetic drug classes. SGLT2 inhibitors have been shown to have the best overall mortality, renal and cardiovascular outcomes. Reduction in hospitalisation for heart failure is particularly consistent. GLP-1 receptor agonists have also showed some benefits, especially in stroke prevention. DPP-4 inhibitors showed neutral effects on cardiovascular outcomes, but may increase the incidence of heart failure. Favourable outcomes observed in trials of SGLT2 inhibitors mean that these should be the preferred second-line option. DPP-4 inhibitors are useful for patients with diabetes at low cardiovascular risk.

significantly reduced major adverse cardiovascular events (MACE), hospitalisation for HF and renal composite outcome compared to placebo. Second, SGLT2 inhibitors were shown to have the greatest cardiovascular and all-cause mortality benefits amongst all three new antidiabetic drug classes. Third, the GLP-1 RA class was the only one that showed reductions in nonfatal stroke events. Finally, the risks of cardiovascular and renal outcomes in DPP-4 inhibitors were found to be neutral when compared to placebo and inferior to the other two drug classes.

The EMPA-REG OUTCOME and CANVAS studies have shown favourable all-cause mortality and cardiovascular outcomes. 11, 12 Meta-analyses of CVOTs confirmed the cardiovascular benefits. 17, 18 Three studies from landmark CVOTs further stratified patients according to baseline characteristics. 21, 22, 23 The benefits of SGLT2 inhibitors were more apparent in patients with a history of HF and reduced ejection fraction. 22, 23 However, baseline risk was higher in this group of patients, possibly accounting for higher absolute risk reductions in cardiovascular outcomes. The DECLARE-TIMI 58 trial enrolled a majority of patients who did not have established atherosclerotic cardiovascular disease (ASCVD), and did not show significant reduction in MACE. 19 This may imply the cardioprotection offered by SGLT2 inhibitors is less evident in such a group of patients . 18 However, analysis from the EMPA-REG OUTCOME trial reported consistent benefits regardless of baseline risks and prior history. 21 Neither of these trials was designed to investigate HF outcomes, but they illustrated the value in identifying patient subgroups that benefit most from SGLT2 inhibitor treatment.

SGLT2 inhibitors are postulated to induce selective volume contraction. 24 Thus, there is a selective reduction of interstitial fluid in contrast to traditional diuretics. 24 Therefore, intravascular volume depletion and fluid retention by the renin-angiotensin-aldosterone system (RAAS) in the long run are limited. 25 SGLT2 inhibitors also inhibit myocardial Na + /H + exchanger (NHE) 1, 5 which has been hypothesised to attenuate cardiac Green lines = beneficial mechanisms; red line = harmful mechanism. SGLT2 = sodium-glucose co-transporter 2.

hypertrophy and HF development. 26 Natriuresis is reported to improve left ventricular (LV) preload conditions, which could be potentiated by additional NHE-3 inhibition at the proximal tubules. 5, 27 Furthermore, SGLT2 inhibitors reduce sympathetic tone and blood pressure (BP), which would improve afterload. 5,28,29 SGLT2 inhibitors are therefore particularly useful for diabetic patients with HF. 3 Moreover, attenuation in endothelial dysfunction and arterial stiffness by reducing oxidative stress has also been reported, bringing potential benefits in vascular diseases. 29, 30 Dapagliflozin and empagliflozin have also shown anti-fibrotic effects in rats and human cardiac fibroblasts. 31, 32 Importantly, SGLT2 inhibitors induce weight loss and increase HDL levels in trials. 11, 12, 26 They also increase lipolysis and reduce inflammation in adipose tissues. 33 The switch from utilisation of glucose to ketones is also believed to be beneficial, especially for cardiac metabolism. 5 All of these mechanisms may help to explain the cardiovascular benefits observed. 11, 12 The DAPA-HF and the EMPEROR-Reduced (NCT03057977) trials showed statistically significant reductions in HF hospitalisation, regardless of history of diabetes. 34 However, the change in mortality did not reach statistical significance in EMPEROR-Reduced. 35 The cardioprotective mechanisms independent of glucose lowering are still not fully understood. The EMPA-HEART trial showed reduction in LV mass and systolic BP in HF with reduced ejection fraction (HFrEF) patients, although the effects on N-terminal pro-B-type natriuretic peptide (NT-proBNP) was insignificant. 36 The EMPERIAL trials (NCT03448419 and NCT03448406) reported no significant improvements in exercise capacity measured by 6-minute walking distance. Improvements in quality of life scores were found in patients with HFrEF but not in those with HF with preserved ejection fraction. Results from on-going EMPA-KIDNEY (NCT03594110), DELIVER (NCT0319213), SMARTEST (NCT03982381), as well as the recently terminated SCORED (NCT03315143) and SOLOIST-WHF (NCT03521934) trials will further elucidate the cardioprotective effects and identify patients who may benefit most from treatment with SGLT2 inhibitors.

SGLT2 inhibitors have shown clear-cut renal benefits in the CREDENCE and DAPA-CKD (NCT03036150) trials, which have also been confirmed in meta-analyses. 17, 37 The natriuresis induced by SGLT2 inhibitors stimulates tubuloglomerular feedback and vasoconstriction in afferent arterioles, thus reducing glomerular hyperfiltration and albuminuria. 26, 38, 39 Concomitant use of RAAS inhibitors is reported to have synergistic effects on renal tubules, slowing down the progression of chronic kidney disease (CKD). 40 The aforementioned shift in metabolic energetics is believed to inhibit oxidative stress and ischaemic injury, not only in myocardium but also in renal tubules. 29, 38 Reduction in BP and body weight as well as increase in uric acid excretion are all postulated as renoprotective mechanisms. 39 The benefits of SGLT2 inhibitors are not always apparent. The effect of SGLT2 inhibitors on stroke events appears to be neutral or even slightly harmful. The EMPA-REG OUTCOME trial detected slight elevations in nonfatal stroke events. 11 In a subgroup analysis of the CANVAS trial, the results showed protective effects against haemorrhagic stroke, yet neutral effects on ischaemic stroke (HR 0.95; 95% CI [0.74-1.22]). 41 BP reduction may account for the prevention of haemorrhagic stroke. 42 However, elevated haematocrit was also observed in the EMPA-REG OUTCOME trial, which might predispose to ischaemic strokes. 11, 42, 43 Although haemoconcentration improves cardiovascular outcomes, the higher blood viscosity may trigger thrombus formation. 27, [42] [43] [44] Although weight loss should protect against ischaemic stroke, compensatory changes may limit weight loss in the long term. 33 Although a harmful effect on stroke has not been confirmed, the protective effect on haemorrhagic stroke may mask the effect on ischaemia if both types of stroke are included as a composite endpoint. [16] [17] [18] Population-wide observational studies may help to evaluate the long-term risk of ischaemic strokes during SGLT2 inhibitor therapy.

Overall, SGLT2 inhibitors have demonstrated the most favourable cardiovascular and all-cause mortality outcomes. Indirect evidence showed overall superiority over DPP-4 inhibitors, which appears to be a class effect. 16, 17 However, superiority between GLP-1 RAs and SGLT2 inhibitors varies across different outcomes. SGLT2 inhibitors are superior in terms of mortality outcomes, yet protection against MACE was similar among GLP-1 RAs and SGLT2 inhibitors. 16, 17 Also, mortality benefits did not reach statistical significance in the CREDENCE and DECLARE-TIMI 58 trials. 19, 37 The CREDENCE trial was prematurely terminated because of overwhelming renal and cardiovascular benefits. A shortened follow-up period limited the power of the study to detect changes in mortality, if present. Besides the CREDENCE trial, other non-empagliflozin trials also failed to show significant changes. 12, 19 Trials of non-empagliflozin SGLT2 inhibitors investigating mortality endpoints are needed to fill in the evidence gap. The combination of RAAS and SGLT2 inhibitors should be advocated as concomitant inhibition appears to achieve better cardiovascular and renal outcomes. 40

The LEADER, HARMONY OUTCOMES and EXSCEL trials demonstrated the cardiovascular safety of GLP-1 RAs. [13] [14] [15] Meta-analyses have reported favourable cardiovascular safety profiles for GLP-1 RAs, especially in MACE and nonfatal stroke events. 16, 17, 45 Improvements in the composite kidney outcome were also detected. 45 However, the benefits were less clear-cut in comparison with SGLT2 inhibitors and somewhat conflicting across trials. Discrepancies in mortality-related outcomes could be due to differences in follow-up periods and study population. Intraclass differences and variations in pharmacokinetics are also possible explanations.

Liraglutide, a long-acting GLP-1 RA, yielded favourable results in the LEADER trial. 13 In addition to glycaemic control, slowing of atherosclerosis and anti-inflammatory actions also account for the benefits of GLP-1 agonism. The interaction between GLP-1 RAs and cardiac GLP-1 receptors has been suggested to improve myocardial ischaemia and protect cardiac progenitor cells. 46 They also exert protective effects independent of GLP-1 receptors. 6 Liraglutide has been reported to induce endothelial nitric oxide synthase via AMP-activated protein kinase signalling. 6 Nitric oxide production improves coronary artery flow and endothelial dysfunction. Besides, GLP-1 RAs inhibit mitochondrial oxidative damage and attenuate reactive oxygen species production. 47 Liraglutide has also been shown to suppress vascular cell adhesion molecule-1 expression in the endothelium. 6 It also improves arterial stiffness and LV function, while reducing NT-proBNP levels, a biomarker for LV dysfunction. 48 Vasodilatory and antioxidant actions could account for some of the antiatherogenic effects in GLP-1 RAs, therefore this drug class may be preferable in diabetic patients with predominant ASCVD risk. 3 However, different results were found in studies of exenatide. 15, 20 Intravenous exenatide in patients after coronary artery bypass grafting surgery did not offer additional cardiovascular benefits compared to parenteral insulin. 20 Differences have been suggested to be related to different immunogenicity profiles and signalling pathways in exendin-4 and GLP-1 based agonists. 46 Exendin-4 based agonists are postulated to be more immunogenic and cause injection site reactions, leading to higher drug discontinuation rate and diminished benefits in the EXSCEL trial. 15, 46 Given the conflicting evidence, CVOTs were conducted to study GLP-1 RAs with different populations and formulations. The FREEDOM-CVO and REWIND trials included injection-free GLP-1 RA with osmotic mini-pump and patients without established cardiovascular background respectively, whereas the PIONEER 6 study investigated oral semaglutide. [49] [50] [51] Mortality outcomes in some of these trials are encouraging, yet the results are inconsistent. 49, 51 GLP-1 RAs uniquely reduced nonfatal stroke events in the LEADER and SUSTAIN-6 trials. 13, 52 The effects were confirmed in our latest NMA (OR 0.88; 95% CI [0.77-0.99]). 17 GLP-1 RAs are reported to be neuroprotective because of the ability to cross the blood-brain barrier and actions on neuroinflammation pathways. 47 Besides atherosclerosis, oxidative stress is considered to be responsible for stroke development. 53 GLP-1 RAs reduce oxidative stress and reactive oxygen species production via p-AKT/endothelial nitric oxide synthase and nuclear factor-κ B p65 pathways. 47 CVOTs are being conducted in order to expand the indication of GLP-1 RAs from ASCVD prevention in diabetes to a broader patient population. Results from the FIGHT trial did not support the use of liraglutide in HF patients, which is not surprising given less clear-cut HF benefits in NMA compared to SGLT2 inhibitors. 17, 54 The on-going EGRABIS1 (NCT02829502) and Lirabolic (NCT04057261) trials also aim to explore the effects of GLP-1

RAs on cardiometabolic markers, such as mean cerebral flow velocity, as well as BP and lipid profiles. Together with the SLIM LIVER (NCT04216589) study in non-alcoholic fatty liver disease patients, these trials will clarify the neuroprotective and cardioprotective mechanisms of GLP-1 RAs independent of glucose levels. This might provide the scientific basis for the benefits of this drug class in the prevention of vascular diseases.

DPP-4 inhibitors did not show cardiovascular benefits in meta-analyses by other researchers and ourselves. 16 significant reductions in MACE, but the inclusion of trials with shorter follow-up periods may limit the robustness of the conclusions. Elevated hospitalisation for HF incidence remains a concern, as reported in the SAVOR-TIMI 53 trial. [55] [56] [57] However, in the EXAMINE and the latest CARMELINA trials, HF incidences were neutral. 58, 59 DPP-4 inhibitors have been reported to inhibit degradation of endogenous peptides other than GLP-1, including stromal-cell-derived factor (SDF) 1, neuropeptide Y and substance P (Figure 2 ). 60 Potentiation of these peptides results in sympathetic activation via cyclic AMP signalling and beta-receptor activation, which may contribute to HF development and cardiac fibrosis. Elevated SDF-1 and substance P levels are also suggested to induce apoptosis of the myocardium. 60 In the SAVOR-TIMI 53 trial, attenuated HF elevation was detected when beta-blockers were used concomitantly. 58, 60 This might imply that chronic sympathetic activation might underlie the inferiority of DPP-4 inhibitors. Notably, most patients enrolled in trials with neutral HF outcomes have concomitant prescriptions for RAAS inhibitors, which could ameliorate the tendency of DPP-4 inhibitors to worsen HF. 58, 59 Combination therapy may counteract the detrimental effects of DPP-4 inhibitors, thus masking the harmful effects. In real life, patient with diabetes are often receiving a RAAS blocker. This makes the drug class useful even in dialysis patients. 8 Nevertheless, DPP-4 inhibitors should be used with caution in patients with HF or at risk of HF.

Observational studies have been conducted to provide insights into the clinical roles of the new antidiabetic drugs. 61 62 The lack of patients enrolled in specific groups also make the use of propensity score matching difficult. Nevertheless, these studies are still valuable because head-to-head randomised controlled trials are lacking. Population-wide observational studies provide a good and generalisable estimation of clinical effects with modest confidence, thus defining the clinical roles of each antidiabetic drug class more clearly.

Choosing an antidiabetic drug class with proven cardiovascular and mortality benefits is now advocated in guidelines. 3,4,63 SGLT2 inhibitors and GLP-1 RAs should be recommended as second-line treatment options after metformin, echoing recommendations by the ADA and the American College of Cardiology. 3, 63 The choice between SGLT2 inhibitors and GLP-1 RAs should be tailor-made according to patient characteristics. SGLT2 inhibitors offered more overall mortality benefits. They should be considered superior in most patients, including those with HF and CKD. 3 However, ischaemia prevention is superior for GLP-1 RAs, thus making them preferable in patients with predominant ASCVD risk. 3 Differences in routes of administration and adverse effect profiles may also play a role in prescription decisions. Most GLP-1 RAs are available as subcutaneous injections, which are inconvenient. Oral semaglutide might make this class attractive to use, but it is expensive. On-going trials, including headto-head trials, are required to address comparative safety and efficacy, as well as possible intraclass differences.

Current evidence confirmed the cardiovascular safety of the three new antidiabetic drug classes, but it is important to appreciate the differences among them. SGLT2 inhibitors show superiority in mortality and cardiovascular events, mainly driven by hospitalisation for HF, and renal events. GLP-1 RAs can reduce nonfatal stroke and MACE, yet inconsistent evidence suggests possible intraclass differences. Both drug classes should now be considered as the preferred second-line treatment in T2D patients after metformin according to patient characteristics. In terms of cardiovascular and renal outcomes, DPP-4 inhibitors have not demonstrated benefits in comparison with placebo and have been proven to be inferior to GLP-1 RAs and SGLT2 inhibitors. In this new era, antidiabetic drugs no longer just control blood glucose, but should also address the cardiovascular risks of T2D patients.

Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes

ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes -2020

International Diabetes Federation. Recommendations For Managing Type 2 Diabetes In Primary Care

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review

GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Pharmacology, physiology, and mechanisms of incretin hormone action

Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

Behind the rosiglitazone controversy

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes

Canagliflozin and cardiovascular and renal events in type 2 diabetes

Liraglutide and cardiovascular outcomes in type 2 diabetes

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Effects of onceweekly exenatide on clinical outcomes in patients with preexisting cardiovascular disease

Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs

Cardiovascular outcomes in trials of new antidiabetic drug classes: a network metaanalysis

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Dapagliflozin and cardiovascular outcomes in type 2 diabetes

Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME ® trial

Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus

Canagliflozin and heart failure in type 2 diabetes mellitus: Results from the CANVAS program

Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis

Effect of SGLT2 inhibitors on body composition, fluid status and reninangiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy

Effects of sodiumglucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action

SGLT-2 inhibitors in heart failure and type-2 diabetes: hitting two birds with one stone?

SGLT2 inhibitors and mechanisms of hypertension

Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects

Minimizing hyperglycemia-induced vascular endothelial dysfunction by inhibiting endothelial sodium-glucose cotransporter 2 and attenuating oxidative stress: implications for treating individuals with type 2 diabetes

Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts

Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG OUTCOME results

Emerging role of SGLT-2 inhibitors for the treatment of obesity

Dapagliflozin in patients with heart failure and reduced ejection fraction

Cardiovascular and renal outcomes with empagliflozin in heart failure

Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

Effects of sodium glucose co-transporter 2 inhibitors on the kidney

SGLT-2 inhibitors in diabetic kidney disease: what lies behind their renoprotective properties

SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease

Canagliflozin and stroke in type 2 diabetes mellitus

Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?

Relationship between hematocrit level and cardiovascular risk factors in a community-based population

How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Heterogeneity and similarities in GLP-1 receptor agonist cardiovascular outcomes trials

Effects of glucagon-like peptide-1 on oxidative stress and Nrf2 signaling

Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes

Intarcia announces successful cardiovascular safety results in phase 3 FREEDOM-CVO trial for ITCA 650, an investigational therapy for type 2 diabetes

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes

Semaglutide and cardiovascular outcomes in patients with type 2 diabetes

Oxidative stress and its role in the pathogenesis of ischaemic stroke

Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: A randomized clinical trial

Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: metaanalysis of placebo-controlled randomized clinical trials

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a metaanalysis of randomized clinical trials

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial

Do DPP-4 inhibitors cause heart failure events by promoting adrenergically mediated cardiotoxicity? Clues from laboratory models and clinical trials

Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: a population based analysis

Association of secondline antidiabetic medications with cardiovascular events among insured adults with type 2 diabetes

ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways

Type 2 diabetes in adults: management. London: NICE

Design and baseline characteristics of the evaluation of ertugliflozin efficacy and safety cardiovascular outcomes trial (VERTIS-CV)

Lixisenatide in patients with type 2 diabetes and acute coronary syndrome

Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes